Browsing Tag
immuno-oncology
35 posts
Regeneron Pharmaceuticals’ LAG-3 gamble stumbles as Keytruda remains hard to beat in melanoma
Regeneron showed a PFS signal but missed the statistical bar. Keytruda remains the oncology benchmark investors still have to beat.
TuHURA Biosciences extends runway into 2028 as HURA investors wait for Merkel cell carcinoma data
TuHURA has bought time with a $50m facility. The harder test is whether IFx-2.0 can deliver before HURA investors lose patience.
Can Namodenoson overcome immunotherapy resistance in advanced pancreatic adenocarcinoma?
Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.
Can Ampligen improve immunotherapy durability in recurrent ovarian cancer treatment?
Can AIM ImmunoTech Inc.’s Ampligen improve immunotherapy durability in ovarian cancer? Explore the Phase 2 data and industry impact.
What AACR 2026 reveals about immune resistance in triple-negative breast cancer
Find out how CytoDyn Inc.’s AACR 2026 data could reshape TNBC immunotherapy and what it means for investors and the oncology market.
How orphan drug status and patent protection shape Ampligen’s commercial and regulatory outlook
Discover how orphan drug status and long-dated patents could shape Ampligen’s regulatory path and commercial value in pancreatic cancer.
How SC-dosed NK cell engagers like GTB-5550 could disrupt cancer care delivery models
GT Biopharma’s GTB-5550 receives FDA clearance with subcutaneous delivery. See how this trial could shift NK immunotherapy into outpatient cancer care.
NK cell immunotherapy moves toward solid tumors as GT Biopharma files IND for GTB-5550 TriKE
Find out how NK cell immunotherapy is moving into solid tumors as GT Biopharma files an IND for its B7-H3-targeted TriKE GTB-5550.
Senhwa Biosciences strikes pivotal supply deal with BeOne Medicines for cold tumor breakthrough
Senhwa Biosciences and BeOne Medicines announce a global clinical trial to tackle cold tumors. Find out how this deal could change cancer immunotherapy.
Why Imugene is using a virus to “mark” tumors for CAR-T attack—and what JW Therapeutics brings to the table
Find out how Imugene and JW Therapeutics plan to make solid tumors respond to CD19 CAR-T therapy using an oncolytic virus strategy.